In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Climb Bio Inc (NASDAQ: CLYM) closed at $3.96 down -4.12% from its previous closing price of $4.13. In other words, the price has decreased by -$4.12 from its previous closing price. On the day, 0.56 million shares were traded. CLYM stock price reached its highest trading level at $4.2399 during the session, while it also had its lowest trading level at $3.93.
Ratios:
For a deeper understanding of Climb Bio Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 18.38 and its Current Ratio is at 18.38. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On October 13, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $9.
On August 15, 2025, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $9.Robert W. Baird initiated its Outperform rating on August 15, 2025, with a $9 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 05 ’26 when RA CAPITAL MANAGEMENT, L.P. bought 7,111 shares for $3.50 per share. The transaction valued at 24,888 led to the insider holds 3,403,429 shares of the business.
RA CAPITAL MANAGEMENT, L.P. bought 213,099 shares of CLYM for $464,556 on Dec 11 ’25. The Director now owns 3,294,856 shares after completing the transaction at $2.18 per share. On Dec 12 ’25, another insider, RA CAPITAL MANAGEMENT, L.P., who serves as the Director of the company, bought 101,462 shares for $2.86 each. As a result, the insider paid 290,181 and bolstered with 3,396,318 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLYM now has a Market Capitalization of 270010368 and an Enterprise Value of 183689360.
Stock Price History:
The Beta on a monthly basis for CLYM is -0.15, which has changed by 1.0547264 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, CLYM has reached a high of $5.19, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 35.78%, while the 200-Day Moving Average is calculated to be 103.82%.
Shares Statistics:
For the past three months, CLYM has traded an average of 1.32M shares per day and 947170 over the past ten days. A total of 68.18M shares are outstanding, with a floating share count of 62.43M. Insiders hold about 8.44% of the company’s shares, while institutions hold 45.76% stake in the company. Shares short for CLYM as of 1767139200 were 1816835 with a Short Ratio of 1.37, compared to 1764288000 on 1881380. Therefore, it implies a Short% of Shares Outstanding of 1816835 and a Short% of Float of 4.95.
Earnings Estimates
. The current rating of Climb Bio Inc (CLYM) is the result of assessments by 2 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.18 and low estimates of -$0.21.
Analysts are recommending an EPS of between -$0.81 and -$0.82 for the fiscal current year, implying an average EPS of -$0.81. EPS for the following year is -$0.81, with 2.0 analysts recommending between -$0.72 and -$0.9.
